Candel Therapeutics
CADL
78 hedge funds and large institutions have $117M invested in Candel Therapeutics in 2025 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 40 increasing their positions, 14 reducing their positions, and 20 closing their positions.
276% more call options, than puts
Call options by funds: $4.56M | Put options by funds: $1.21M
186% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 14
1.12% more ownership
Funds ownership: 44.86% → 45.98% (+1.1%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3% less capital invested
Capital invested by funds: $120M → $117M (-$3.16M)
5% less funds holding
Funds holding: 82 → 78 (-4)
20% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.91M |
| 2 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$3.81M |
| 3 |
BlackRock
New York
|
+$2.77M |
| 4 |
ACA
Acorn Capital Advisors
New York
|
+$2.2M |
| 5 |
Two Sigma Investments
New York
|
+$1.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$10.7M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$1.19M |
| 3 |
Millennium Management
New York
|
-$1.18M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$546K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$540K |
CADL Hedge Fund Activity: Q2 2025 in Review
78 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Candel Therapeutics (CADL) for Q2 2025, worth a combined $117M — down 2.6% from $120M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of CADL and 16 opened new positions — a net loss of 4 holders — while 14 trimmed existing stakes and 40 added.
The largest buyer was Fidelity Investments, adding an estimated $5.91M. The largest seller was Baker Bros. Advisors, cutting an estimated $10.7M.
- 78 institutional investors held Candel Therapeutics (CADL) as of Q2 2025, down from 82 in Q1 2025.
- Funds reported $117M of Candel Therapeutics stock for Q2 2025, down 2.6% quarter-over-quarter.
- 16 funds opened new Candel Therapeutics positions in Q2 2025 and 20 closed out, a net change of -4 holders.
- The largest Candel Therapeutics buyer in Q2 2025 was Fidelity Investments, an estimated $5.91M added.
- The largest Candel Therapeutics seller in Q2 2025 was Baker Bros. Advisors, an estimated $10.7M sold.
Based on aggregated 13F filings for Q2 2025.